Branch of medicine that involves the medical care of infants, children, and adolescents
POPULARITY
Categories
458 episodes with Pediatrics
404 episodes with Pediatrics
229 episodes with Pediatrics
144 episodes with Pediatrics
114 episodes with Pediatrics
119 episodes with Pediatrics
164 episodes with Pediatrics
248 episodes with Pediatrics
110 episodes with Pediatrics
125 episodes with Pediatrics
91 episodes with Pediatrics
125 episodes with Pediatrics
92 episodes with Pediatrics
139 episodes with Pediatrics
85 episodes with Pediatrics
64 episodes with Pediatrics
67 episodes with Pediatrics
71 episodes with Pediatrics
51 episodes with Pediatrics
43 episodes with Pediatrics
48 episodes with Pediatrics
52 episodes with Pediatrics
118 episodes with Pediatrics
116 episodes with Pediatrics
43 episodes with Pediatrics
42 episodes with Pediatrics
45 episodes with Pediatrics
65 episodes with Pediatrics
41 episodes with Pediatrics
28 episodes with Pediatrics
37 episodes with Pediatrics
32 episodes with Pediatrics
29 episodes with Pediatrics
25 episodes with Pediatrics
30 episodes with Pediatrics
13 episodes with Pediatrics
27 episodes with Pediatrics
27 episodes with Pediatrics
29 episodes with Pediatrics
34 episodes with Pediatrics
31 episodes with Pediatrics
36 episodes with Pediatrics
31 episodes with Pediatrics
41 episodes with Pediatrics
24 episodes with Pediatrics
13 episodes with Pediatrics
58 episodes with Pediatrics
73 episodes with Pediatrics
25 episodes with Pediatrics
46 episodes with Pediatrics
18 episodes with Pediatrics
18 episodes with Pediatrics
14 episodes with Pediatrics
13 episodes with Pediatrics
This 'Media Buzz Meter' first aired on December 18th, 2025… Howie Kurtz on President Trump's address to the nation, House Republicans offering an alternative to Obamacare, and Secretary RFK Jr. terminating grants to the American Academy of Pediatrics over federal vaccine policy disagreements. Follow Howie on Twitter: @HowardKurtz For more #MediaBuzz click here Learn more about your ad choices. Visit podcastchoices.com/adchoices
This week we review a recent report on LV strain following the Ross operation. Can this sort of functional analysis help predict remodeling after aortic valve replacement? How can the type of Ross potentially affect heart function after the operation? Why might some parameters of LV strain improve but others not following surgery? Can preoperative strain measurements predict perioperative course? How does the addition of a Konno to a Ross change the outcomes of function? We speak with Chief of Cardiovascular Surgery at Primary Children's Hospital in Utah, Dr. S. Adil Husain and 3rd year integrated cardiac surgical resident Michal Schaffer of the University of Utah about these and other topics related to LV function following the Ross operation in children. · DOI: 10.1007/s00246-025-04124-9
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Pediatric Abuse from our Pediatrics section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
We discuss the shift to prehospital blood to treat shock sooner. Hosts: Nichole Bosson, MD, MPH, FACEP Avir Mitra, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Prehospital_Transfusion.mp3 Download Leave a Comment Tags: EMS, Prehospital Care, Trauma Show Notes Core EM Modular CME Course Maximize your commute with the new Core EM Modular CME Course, featuring the most essential content distilled from our top-rated podcast episodes. This course offers 12 audio-based modules packed with pearls! Information and link below. Course Highlights: Credit: 12.5 AMA PRA Category 1 Credits™ Curriculum: Comprehensive coverage of Core Emergency Medicine, with 12 modules spanning from Critical Care to Pediatrics. Cost: Free for NYU Learners $250 for Non-NYU Learners Click Here to Register and Begin Module 1 What is prehospital blood transfusion Administration of blood products in the field prior to hospital arrival Aimed at patients in hemorrhagic shock Why this matters Traditional US prehospital resuscitation relied on crystalloid ED and trauma care now prioritize early blood Hemorrhage occurs before hospital arrival Delays to definitive hemorrhage control are common Earlier blood may improve survival Supporting rationale ATLS and trauma paradigms emphasize blood over fluid National organizations support prehospital blood when feasible EMS already manages high risk, time sensitive interventions Evidence overview Data are mixed and evolving COMBAT: no benefit PAMPer: mortality benefit RePHILL: no clear benefit Signal toward benefit when transport time exceeds ~20 minutes Urban systems still experience long delays due to traffic and geography LA County median time to in hospital transfusion ~35 minutes LA County program ~2 years of planning before launch Pilot began April 1 Partnerships: LA County Fire Compton Fire Local trauma centers San Diego Blood Bank 14 units of blood circulating in the field Blood rotated back 14 days before expiration Ultimately used at Harbor UCLA Continuous temperature and safety monitoring Indications used in LA County Focused rollout Trauma related hemorrhagic shock Postpartum hemorrhage Physiologic criteria: SBP < 70 Or HR > 110 with SBP < 90 Shock index ≥ 1.2 Witnessed traumatic cardiac arrest Products: One unit whole blood preferred Two units PRBCs if whole blood unavailable Early experience ~28 patients transfused at time of discussion Evaluating: Indications Protocol adherence Time to transfusion Early outcomes Too early for outcome conclusions California collaboration Multiple active programs: Riverside (Corona Fire) LA County Ventura County Additional programs planned: Sacramento San Bernardino Programs meet monthly as CalDROP Focus on shared learning and operational optimization Barriers and concerns Trauma surgeon concerns about blood supply Need for system wide buy in Community engagement Patients who may decline transfusion Women of childbearing age and alloimmunization risk Risk of HDFN is extremely low Clear communication with receiving hospitals is essential Future direction Rapid national expansion expected Greatest benefit likely where transport delays exist Prehospital Blood Transfusion Coalition active nationally Major unresolved issue: reimbursement Currently funded largely by fire departments Sustainability depends on policy and payment reform Take-Home Points Hemorrhagic shock is best treated with blood, not crystalloid Prehospital transfusion may benefit patients with prolonged transport times Implementation requires strong partnerships with blood banks and trauma centers Early data are promising, but patient selection remains critical National collaboration is key to sustainability and future growth Read More
In this podcast, Series 4, Chapter 6, Dr. Barsuk interviews Dr. Martin Pusic, Associate Professor of Pediatrics and Emergency Medicine at Harvard Medical School and Senior Associate Faculty for Boston Children's Hospital and Scholar-in-Residence at the Brigham Education Institute, Brigham & Women's Hospital in Boston, MA. Dr. Pusic serves as Director of the American Board of Medical Specialties Research and Education Foundation. He is a medical doctor practicing as a pediatric emergency physician but also received a Doctor of Philosophy in Cognition and Learning. His research focuses on learning analytics and the role and impact of research, data, and informatics on medical education and learning. Drs. Barsuk and Pusic talk about research in medical education and initiatives at the ABMS.
Welcome to Season 2 of the Orthobullets Podcast. Today's show is Podiums, where we feature expert speakers from live medical events. Today's episode will feature Dr. John Ketz is titled "Rigid Adult Flatfoot."Follow Orthobullets on Social Media:FacebookInstagramTwitterLinkedInYouTube
Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/ Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com
Anxiety in children can serve as a safeguard or become profoundly disruptive. For pediatricians, distinguishing between developmentally appropriate worry, generalized anxiety disorder and clinically significant anxiety is rarely straightforward. In this episode, we explore how anxiety presents across childhood, why it is more than "just nerves" and how pediatricians can play a key role in early identification and support. Benjamin Mullin, PhD, is the lead psychologist of the Colorado OCD and Anxiety Program (COAP) at Children's Hospital Colorado, as well as an associate professor at the University of Colorado School of Medicine. He is also the Leslie and William Vollbracht Family Chair in Stress and Anxiety Disorders. Some highlights from this episode include: The realities of anxiety in kids When treatment is appropriate and when to refer Helping families understand anxiety without stigmatizing or minimizing their children's experience Strategies that work for long-term management For more information on Children's Colorado, visit: childrenscolorado.org.
Host: Dr. Susan Buttross, Professor of Pediatrics at the University of Mississippi Medical Center, and Abram NanneyTopic: Today's episode of Relatively Speaking is a special best of compilation of some conversations Dr. Buttross and I have had where she compared and contrasts different emotions with their extremes. For example, are you afraid or do you have a phobia? Are you moody or are you living with a diagnosable mood disorder? You can join the conversation by sending an email to: family@mpbonline.org. Hosted on Acast. See acast.com/privacy for more information.
In this episode of Bowel Sounds, hosts Dr. Jordan Whatley and Dr. Jenn Lee talk to Dr. Naylor Brownell, Pediatric Gastroenterologist and Co-Director of the Pancreatic Disorders Program at the Children's Hospital of Philadelphia, who provides care in the Jill and Mark Fishman Center for Lymphatic Disorders. We talk about lymphatic conditions and their effect on the GI tract, as well as the diagnosis and management of primary intestinal lymphangiectasia.Learning Objectives1. Understand the structure and function of the lymphatic system2. Describe the causes of protein losing enteropathy (PLE) and how they are diagnosed3. Understand the management of children with primary intestinal lymphangiectasiaLinkshttps://www.chop.edu/centers-programs/jill-and-mark-fishman-center-lymphatic-disordersSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.
„Geh doch mal zur Osteopathin, das hilft bestimmt!“ – ein Satz, den fast alle Eltern irgendwann hören. Aber was steckt eigentlich hinter der Kinderosteopathie? In dieser Folge sprechen wir mit dem Kinder- und Jugendarzt Pierre Teichmann darüber, warum sie so beliebt ist, welche Versprechen sie gibt und was die Wissenschaft wirklich dazu sagt. +++Shownotes:Pierres Artikel "Wie der Ast gebogen wird, so wächst der Baum": https://kinderaerzte-im-aerztehaus.de/wp-content/uploads/2025/06/Thema-Kinderosteopathie.pdf, Pierre erwähnte folgende Studien: KiSS/ Asymmetrie: Sacher, R. et al (2024). Multicentric RCT on one-time manual medicine treatment of infantile postural and motor asymmetries (KISS)—Spreewald trial II. Manuelle Medizin, 62(2), 102–109. https://doi.org/10.1007/s00337-024-01046-0, Philippi, H. et al (2006). Infantile postural asymmetry and osteopathic treatment: A randomized therapeutic trial. Developmental Medicine and Child Neurology, 48(1), 5–9. https://doi.org/10.1017/S001216220600003X, Metaanalyse muskuloskeletale Beschwerden/ Rückenschmerzen: Ceballos-Laita, L. et al (2024). Is Osteopathic Manipulative Treatment Clinically Superior to Sham or Placebo for Patients with Neck or Low-Back Pain? A Systematic Review with Meta-Analysis. In Diseases (Bd. 12, Nummer 11). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/diseases12110287, Metaanalysen kraniosakrale Therapie: Ceballos-Laita, L. et al (2024). Is Craniosacral Therapy Effective? A Systematic Review and Meta-Analysis. In Healthcare (Switzerland) (Bd. 12, Nummer 6). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/healthcare12060679, Amendolara, A. et al (2024). Effectiveness of osteopathic craniosacral techniques: a meta-analysis. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1452465, Reviews Kinderosteopathie: Posadzki, P. et al (2013). Osteopathic manipulative treatment for pediatric conditions: A systematic review. In Pediatrics (Bd. 132, Nummer 1, S. 140–152). American Academy of Pediatrics. https://doi.org/10.1542/peds.2012-3959, Posadzki, P. et al (2022). Osteopathic Manipulative Treatment for Pediatric Conditions: An Update of Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 11(15). https://doi.org/10.3390/jcm11154455, Franke, H. et al (2022). Effectiveness of osteopathic manipulative treatment for pediatric conditions: A systematic review. Journal of Bodywork and Movement Therapies, 31, 113–133. https://doi.org/10.1016/j.jbmt.2022.03.013, exzessives Schreien und Osteopathie: Schwerla, F. et al (2021). Osteopathic Treatment of Infants in Their First Year of Life: A Prospective Multicenter Observational Study (OSTINF Study). Complementary Medicine Research, 28(5), 395–406. https://doi.org/10.1159/000514413, Cabanillas-Barea, S. et al (2023). Systematic review and meta-analysis showed that complementary and alternative medicines were not effective for infantile colic. In Acta Paediatrica, International Journal of Paediatrics (Bd. 112, Nummer 7, S. 1378–1388). John Wiley and Sons Inc. https://doi.org/10.1111/apa.16807, Carnes, D. et al (2024). Usual light touch osteopathic treatment versus simple light touch without intent in the reduction of infantile colic crying time: A randomised controlled trial. International Journal of Osteopathic Medicine, 51. https://doi.org/10.1016/j.ijosm.2024.100710, Stellungnahmen Gesellschaft für Neuropädiatrie: Gesellschaft für Neuropädiatrie e.V. (GNP). (2005). Stellungnahme: Manualmedizinische Behandlung des KISS-Syndroms und Atlastherapie nach Arlen. In Manuelle Medizin (Bd. 43, Nummer 2). Springer Science and Business Media LLC. https://doi.org/10.1007/s00337-005-0351-y, Gesellschaft für Neuropädiatrie (GNP), Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ), Berufsverband der Kinder- und Jugendärzte (BVKJ), & Deutsche Akademie für Kinder- und Jugendmedizin (DAKJ). (2015). Stellungnahme Osteopathie bei Kindern. https://www.dgspj.de/wp-content/uploads/service-stellungnahme-osteopathie-2015.pdf, Weitere Literatur: Teichmann, P. (2025). Kinderosteopathie - Falsche Versprechen. Deutsche Hebammen Zeitschrift (DHZ), 77(4), 66–71. https://staudeverlag.de/falsche-versprechen/, Maier , J. (2016). In guten Händen? DIE ZEIT. https://www.zeit.de/2016/33/osteopathie-babies-orthopaedie-gesundheit-medizin-saeuglinge/+++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/Wunschkind_Podcast ++++++ Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++ Wir verarbeiten im Zusammenhang mit dem Angebot unserer Podcasts Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.htmlUnsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.
Welcome to Season 2 of the Orthobullets Podcast.Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Osteomyelitis - Pediatric from our Pediatrics section at Orthobullets.com.Follow Orthobullets on Social Media:FacebookInstagram TwitterLinkedInYouTube
Welcome to Season 2 of the Orthobullets Podcast.In this episode, we review the high-yield topic of Duchenne Muscular Dystrophy from the Pediatrics section.Follow Orthobullets on Social Media:FacebookInstagramTwitterLinkedInYouTube
This week we end 2025 with a Pediheart tradition - an episode on personal finance for medical professionals with noted authority on index investing and personal finance, Mr. Paul Merriman. Paul is a retired investment advisor who now has a popular podcast "Sound Investing" and website in which he offers advice on investing for 'do it yourself' investors. In this week's episode, the 5th of his visits to Pediheart, Mr. Merriman discusses 'factor investing' via index-like ETF's and funds. He also reviews who he believes might benefit from a financial advisor, what sort of advisor most should seek out and why he believes that many do not need one if they can 'stay the course'. Resources mentioned in today's podcast are below. Wishing all a happy and healthy new year in 2026. Paul's website:https://www.paulmerriman.com/#gsc.tab=0'Best In Class' ETF's:https://www.paulmerriman.com/Best-in-Class-ETF-Recommendations2025#gsc.tab=0Sound Investing 'Quilt Charts':https://irp.cdn-website.com/6b78c197/files/uploaded/(K)_Quilt_Charts_(1928-2024)_-_2024_Returns_(1).pdfDFA 'Turn Out The Noise':https://www.dimensional.com/filmAs a reminder, all of the information provided in this week's episode should be considered entertainment and all financial decisions should be vetted with professionals or knowledgeable and trusted friends/family.
Today's West Coast Cookbook & Speakeasy Podcast for our especially special Daily Special, Blue Moon Spirits Fridays, is now available on the Spreaker Player!Starting off in the Bistro Cafe, Ghislaine Maxwell is caught plotting with Trump as the cover-up continues to be exposed.Then, on the rest of the menu, The American Academy of Pediatrics sued the MAGA HHS for cutting funds for children's health programs; the MAGA DOJ sued Illinois Governor Pritzker over state laws protecting immigrants at courthouses and hospitals; and, a federal judge blocked Trump's effort to strip the security clearance from a prominent attorney who represented whistleblowers.After the break, we move to the Chef's Table where an independent counsel demanded a 10-year prison term for South Korea's ousted President Yoon Suk Yeol in the first of seven criminal cases over his ill-fated attempt to impose martial law in 2024; and, Somalis vote in the first one-person, one-vote local election since 1969.All that and more, on West Coast Cookbook & Speakeasy with Chef de Cuisine Justice Putnam.Bon Appétit!The Netroots Radio Live PlayerKeep Your Resistance Radio Beaming 24/7/365!“Structural linguistics is a bitterly divided and unhappy profession, and a large number of its practitioners spend many nights drowning their sorrows in Ouisghian Zodahs.” ― Douglas Adams "The Restaurant at the End of the Universe"Become a supporter of this podcast: https://www.spreaker.com/podcast/west-coast-cookbook-speakeasy--2802999/support.
Follow-ups: Nicki Minaj at risk of losing $20M Los Angeles home @1:22 Oklahoma removes instructor @3:35 Oklahoma Supreme Court blocks new social studies standards @6:44 News: Epstein files…what we expected @8:58 Venezuela assets @22:25 Hegseth overhauling chaplain corps @27:23 Trump moves to dismantle major US climate research center in Colorado @28:32 Health/Medicine/Science: Texas measles outbreak hardened Mennonites against vaccines @30:47 AAP hearing @32:51 American Academy of Pediatrics loses funding @37:40 CDC awards $1.6 million for hepatitis B vaccine study @41:30 Consumer Health Digest - Nutrition influencer @37:39 Religious Nonsense: Flag linked to Christian nationalism, Jan. 6 hung at Education Dept. @41:29 Lynching in Bangledesh @43:38 Politics: Trump battleship @45:07 Kennedy Center @47:39 Is he offering to resign? @50:17
This episode breaks down the major misconceptions about ADHD treatment and clarifies what decades of research, major clinical guidelines, and leading experts actually recommend. Ryan and Mike explain why weekly talk therapy is not an evidence-based treatment for ADHD, why parent training and environmental structure are consistently shown to improve outcomes, and how parents can make informed decisions without getting pulled into common myths.Find Mike @ www.grownowadhd.com & on IGFind Ryan @ www.adhddude.com & on Youtube{{chapters}}[00:00:00] Start[00:02:21] What clinical guidelines actually recommend[00:05:27] Dr. Barkley's research on effective ADHD treatments[00:09:11] Evidence on CBT, DBT, and play therapy[00:19:21] Why office-based therapy doesn't translate to real-world behavior[00:22:29] Rumination and how talk-heavy approaches can backfire[00:31:19] Treatments with the strongest evidence (medication, parent training)Citations:1. AAP Guideline (Parent Training + Medication as First-Line)Wolraich, M. L., et al. (2019). Clinical practice guideline for ADHD in children and adolescents. Pediatrics, 144(4), e20192528.2. AACAP Treatment Parameter (Medication + Behavioral)Pliszka, S. R., & AACAP Work Group. (2007). Practice parameter for ADHD. JAACAP, 46(7), 894–921.3. Barkley: ADHD as Performance DisorderBarkley, R. A. (2012). Executive functions. Guilford Press.Barkley, R. A. (2015). ADHD: Handbook for diagnosis and treatment (4th ed.). Guilford Press.4. CBT Evidence (Adolescents/Adults, Not Young Children)Safren, S. A., et al. (2010). CBT vs relaxation for adults with ADHD. JAMA, 304(8), 875–880.Solanto, M. V. (2011). CBT for adult ADHD. Guilford Press.Langberg, J. M., et al. (2008). Organization skills intervention for adolescents. JCCP, 76(6), 967–982.5. DBT-Informed (Pilot Trials, Emotion Dysregulation)Murray, D. W., et al. (2022). DBT skills group for adolescents with ADHD. J Attention Disorders, 26(11), 1421–1430.6. Play Therapy (Insufficient Evidence)Hassan, R. A., & Shaker, N. S. (2014). CBPT for ADHD symptoms. Int J Psychology & Behavioral Sciences, 4(6), 221–229.7. EF Skills: Experience-Based, Not Language-BasedBarkley, R. A. (2012). Executive functions. Guilford Press.8. Rumination and ADHDOstojic, D., et al. (2021). Mind wandering and rumination in youth with ADHD. J Abnormal Child Psychology, 49, 1203–1216.Seymour, K. E., et al. (2014). Emotion regulation mediates ADHD-depression relationship. J Abnormal Child Psychology, 42, 611–621.9. Time Blindness/Temporal ProcessingToplak, M. E., & Tannock, R. (2005). Time perception deficits in ADHD. J Abnormal Child Psychology, 33(5), 639–654.Barkley, R. A., et al. (2008). ADHD in adults: What the science says. Guilford Press.10. Parent Behavior Training (Evidence-Based)Chronis, A. M., et al. (2006). Evidence-based treatments for children with ADHD. Clinical Psychology Review, 26(4), 486–502.Evans, S. W., et al. (2014). Evidence-based treatments for ADHD. JCCAP, 43(4), 527–551.11. Medication as First-LineFaraone, S. V., et al. (2021). Stimulant effectiveness and safety. World Psychiatry, 20(3), 314–329.Swanson, J. M., et al. (2017). MTA study long-term outcomes. JAACAP, 56(3), 228–240.
Dive into decision support tools and management options for primary care mental health conditions that often stump the primary care clinician.
In this episode of the special series, "Pathways to Pediatrics," hosts David Hill, MD, FAAP, and Joanna Parga-Belinkie, MD, FAAP, interview Cora Breuner, MD, MPH, FAAP. Dr. Breuner talks about how her time in the Navy inspired her to pursue a career as a pediatrician. She discusses her passions for Zumba, art and music, and how personal loss and a health crisis shaped her approach to care. For resources go to aap.org/podcast.
In this Q&A episode, host Paul Wirkus, MD, FAAP and guest Tim Bahr, MD, FAAP address important clinical questions surrounding hyperbilirubinemia, with a focus on longer-term complications and complex presentations. The discussion explores outcomes associated with severe or prolonged hyperbilirubinemia, including cases with late presentation or persistent jaundice, and how these scenarios may differ from typical newborn courses. We also review key considerations for escalation of care, including when transfer to a higher level of care is warranted and how to make those decisions in real-world practice. This episode offers practical guidance to support timely recognition, appropriate management, and improved outcomes for infants at risk. For more information about available credit, visit vCurb.com.ACCME Accreditation StatementThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Colorado Medical Society through the joint providership of Kansas Chapter, American Academy of Pediatrics and Utah Chapter, AAP. Kansas Chapter, American Academy of Pediatrics is accredited by the Colorado Medical Society to provide continuing medical education for physicians. AMA Credit Designation StatementKansas Chapter, American Academy of Pediatrics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Host: Dr. Susan Buttross, Professor of Pediatrics at the University of Mississippi Medical Center, and Abram NanneyTopic: The holiday season is here, and everywhere we look, there's a push for cheer, bright lights, and festive gatherings. But for many of us, the holidays will feel different this year. There's an empty chair at the table, a silence in the home, a loved one that's missing. Today we'll be talking about navigating the season while at the same time holding the weight of grief and missing a loved one who has left an empty place at the tableYou can join the conversation by sending an email to: family@mpbonline.org. Hosted on Acast. See acast.com/privacy for more information.
Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USADoctors Beggs and Parsons discuss the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at the MDA 2025 conference in Dallas, Texas, in March 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established. In contents of this podcast, shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The ASPIRO clinical trial is on clinical hold since September 2021.In this part, Doctor Beggs will provide an explanation of AAV-mediated gene therapies.Alan Beggs, PhDAAV vectors, which I'm going to be talking about more today, or Adeno associated viral vectors are small viruses. Their DNA gets delivered into the cell and remains extrachromosomal. There are very rare occasional integrations, but the risk of oncogenesis as a result is significantly lower as a consequence of remaining extrachromosomal, though, we do have to think about what happens as the cells divide and potentially the durability of treatment is more limited.There have been a lot of movement and development over the years, starting back in the 1980s when the first AAV genomes were isolated and sequenced. This led to a development of methods to produce recombinant AAVs that would lack the genes necessary for viral replication, but contain a therapeutic gene you wish to deliver. Through this, the structure of AAVs have been developed. There have been isolation of a number of naturally occurring variants. You've heard of AAV8, AAV9, also RH 74, derived from a rhesus monkey for the RH. These have all been used in clinical trials. Then at the end I'll talk a little bit about directed evolution methods to actually engineer capsids with particular properties that are beneficial.Throughout this we've identified some of the issues that arise in this. It was initially thought that AAV vectors were non-immunogenic, but in fact there are immune responses not just to the viral payload to the therapeutic protein, but also to the viral vectors, and you're going to hear about that from Doctor Parsons. Over time, as we've come to understand these challenges, we've also been developing approaches to mitigate them. In terms of clinical trials and treatments, the very first studies were done back in the 1970s.By the early 2000, the very first clinical therapeutic was approved in China. It was actually an oncolytic virus carrying a p53 gene to treat head and neck cancers. By now there are over 40 approved treatments for various types of AAV delivered gene therapies. Of course, the ones we know a lot about are Zolgensma, which was approved in 2019, and Elevidys, which was approved last year. A number of challenges and then also a number of approaches to overcome those challenges. First of all, the preclinical data are not always sufficient to predict the response of a human patient.For example, in X-linked myotubular myopathy we had mouse and dog models that exhibited a myopathy but nothing else, and yet when we treated human patients, we discovered that patients with X-linked myotubular myopathy actually had a previously only poorly recognized hepatopathology that led to potential liver consequences following gene therapy. The animal models don't always predict the clinical outcome in humans.Also, we have small disease populations. These are rare diseases. It's important to understand the natural history of these diseases, understand the heterogeneity among the clinical population. It's very important to engage with families and with patients and communities, understand who might be at increased risk to treatment with one of these. This feeds into safety considerations. We need to think also about some of the immune responses. I think we're starting to learn, for example, with the gene therapies for Duchenne, and we know this from SMA that some patients get into trouble and others don't. We need to understand why that may be, and we don't know about the long term effects. This has been very recent.
Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USAThe challenges that you've heard about are real. Some of them I think we could have foreseen others. There was no way to know until we actually started treating patients in clinic. But we now know that there are immune responses and also responses just to the viral load. As Julie mentioned, we're giving massive doses to these patients on the order of one times ten to the 14 viral genomes per kilogram.Think about the fact that when these capsids are manufactured, there's a certain percentage of empty capsid. The amount of protein that's being delivered to these patients can be massive. One of the approaches to mitigate some of the risk would be to lower the dose. While early studies demonstrated that in order to get adequate delivery to skeletal muscle, you need to give these very large doses. But what if we could engineer a viral capsid that would be potent at lower doses?There has been quite a bit of research in this area that's ongoing, and some new next generation vectors that are just starting to enter the clinic. In particular, there are a class of Myotropic viral vectors or capsids so-called RGD vectors. RGD refers to arginine, glycine, and aspartic acid, which are three residues which, when present at a particular point in the viral capsid proteins interact with integrin receptors that are specific for skeletal muscle. These viral capsids home to skeletal muscle and can deliver their genetic payload at much lower doses. There was one group of these developed in Germany by Theo Grimm's lab.These were the so-called AAV Myos, and simultaneously in Boston at the Broad Institute, a group of capsids was developed that were called Myo AAV. These were both based off of an AAV nine backbone. It's basically an AAV nine legacy vector with these three amino acids changed. Now Solid Biosciences also has their own independently derived vector that I believe is also an RGD vector. These vectors give us the potential then for more efficient and specific delivery to muscle cells.They may or may not target the liver depending on the particular virus. Some of them the risk to the liver is mitigated by delivering a lower dose. You can also develop these vectors in a way that will be liver targeted, that specifically less of it gets delivered to the vectors. These would be really, in my mind potentially third generation vectors.Strategies, there are a number of strategies. You heard about the immunomodulation regimens. I just talked about optimizing vector design. Also, Doctor Parsons mentioned earlier the fact that where you deliver so zolgensma is delivered Intrathecally. We get it to the place we need it, and we're less likely to have off target effects through other tissues.Then improved manufacturing is very important. I mentioned the fact that every viral preparation contains empty capsids. There are ways to minimize the production of empty capsids, and also effective ways to filter out and remove those empty capsids. This is actually a very important aspect that is being developed further by the CMO community. Then in summary, I think it's important to take a holistic approach when we're thinking about the development of AAV based gene therapies for neuromuscular disease.It starts from the fact that for any given disease we're interested in, we need to define the genetic etiology. Since these are gene directed therapies. We need to pay careful attention to the preclinical animal models. How accurately do they really reflect the human condition? Or are there potentially responses in our human patients that we haven't experienced in the animals? It's important to understand the natural history and the patient population.Recognize that there's extensive heterogeneity, not just in age and severity, but also potentially in underlying susceptibilities in our patients. We have a group of toxicities that we know about and can anticipate. But as Julie was saying, you need to be really careful and think about any potential unexpected SAEs. And then finally I mentioned the manufacturing aspect, the development of newer vectors and quality control aspects that go into making a safe and effective therapeutic.In the next part. Doctor Parsons will discuss clinical safety and efficacy observed in AAV mediated gene therapy programs in DMD, SMA, and XLMTM.
Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe ASPIRO Clinical Trial is on clinical hold since September 2021. In this part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.Question: Is there a standardized immunomodulation regimen being considered for gene therapy?Julie A. Parsons, MDAs I mentioned, right now, I think there are a number of different concepts that are being utilized. We don't really have a recommended standard regimen at this point. There are a number of different trials that are ongoing looking at trying to answer this question. In some of the clinical trials, there is an immune modulating regimen that is being put in place but being looked at. There isn't anything that we have as a standard at this moment for all gene transfer therapies, but I'm hopeful that we will come up with something that really makes sense in each patient population as we go forward with specific gene transfer therapies.Question: What are the long-term implications, safety and efficacy of a one-time gene therapy in pediatric patients with neuromuscular diseases?Alan Beggs, PhDOne question is the efficacy. For example, Donovan Decker's story, he had an experimental treatment of one muscle. It was a phase one safety trial, and he knew that nothing was going to come of it in terms of direct benefit to him. As a result, though, 25, 30 years later, he still has a tighter against AAV vectors. He's not a candidate for gene therapy under current protocols, although there's a lot of work going on to redosing. But for now, it's a one-time treatment. What you get is what you get, and there's not a chance to go back and do it again.The other question is durability. We really don't know about the long-term durability for these treatments. I should say that, for example, in the studies that we did, David Mack, who's here in the audience, managed a dog colony for a dog model of excellent tubular myopathy. Those animals lived 10 years in a... We never used the C-word, but they were cured. They were healthy, happy, normal dogs who would have had to be put down at 6 months of age otherwise. And then, as we heard, I'll let you talk about the concern for unanticipated SAEs as time goes on, but I think there's other aspects we need to think about.Julie A. Parsons, MDYeah. I think that this is really the key question that all of us are going to need to help answer over the next several years. Efficacy, we're looking at outcomes, and outcomes come in a variety of flavors. I think we do a decent job with motor outcomes. We don't do a decent job with some other outcomes. I think we need to look more broadly in terms of what we mean in terms of beneficial outcomes and really take some of those cues from the patients themselves about if these are efficacious treatments, because, again, the risk is high as we deliver these agents, and we need to know that it's worth it to the patients and families.In terms of safety, we're working on it. There are all sorts of things that are coming forward as issues with these patients. I think that collectively as a community, that our responsibility is to follow patients for the long term. There are lots of registries and outcome studies. We're not very good as a community about reporting adverse events to central groups. We're not great about broadcasting that to each other in real-time. I think those are things that we really need to work on as a community in terms of helping with the safety issues so that we all have a communal better understanding of what some of those issues are.
Dr. Sue McCreadie, MD, shares her inspiring path from pediatrician to holistic practitioner and life coach for women in midlife. She opens up about loss, resilience, and how “soulful medicine” transforms not just health, but relationships and purpose. Discover how self-love, emotional mastery, and the courage to follow life's breadcrumbs create lasting impact for families and future generations. https://www.drsuemccreadie.com/Inspire Vision Podcast is broadcast on K4HD Radio (www.k4hd.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com). Inspire Vision Podcast TV Show is viewed on Talk 4 TV (www.talk4tv.com). Inspire Vision Podcast is also available on Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.
December 21, 2025; 9am: Health and Human Services terminated millions of dollars in grants to the American Academy of Pediatrics after the group previously criticized health secretary Robert F. Kennedy Jr's changes to the federal vaccine policy. The health secretary is also expected to announce sweeping changes to how American children should be immunized in the new year. Dr. Karen Remley, the former CEO of the American Association of Pediatrics, joins “The Weekend” to share what this could mean for families.For more, follow us on social media:Bluesky: @theweekendmsnow.bsky.socialInstagram: @theweekendmsnowTikTok: @theweekendmsnow To listen to this show and other MS podcasts without ads, sign up for MS NOW Premium on Apple Podcasts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Happy Holidays, everyone!
What is a call? How does a person know if God is calling them to mission service? Join in a discussion as these and other questions are addressed.
Today's HighWire pulls no punches. Del breaks down HHS's decision to withdraw funding from the American Academy of Pediatrics and the media reaction to RFK Jr.'s bold move. Jefferey Jaxen reports on the quiet return of flu lockdowns overseas—and the next pandemic narrative already taking shape. Then, Jefferey examines what's truly at stake as the AI race threatens to replace human labor at scale. Finally, epidemiologist Nick Hulscher, MPH, joins Del in-studio to reveal new findings from a reanalysis of the Henry Ford “vaxxed vs. unvaxxed” data—results that could redefine modern public health.Guests: Nicolas Hulscher, MPHBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.
Today's Headlines: It's officially Epstein Files Friday — meaning the DOJ is legally supposed to release the files today, per the law Trump signed 30 days ago. Coincidentally, House Speaker Mike Johnson sent Congress home early for the holidays, neatly avoiding being in the building when the files are either released or… not. Meanwhile, House Democrats dropped 70 more photos from Epstein's estate, including plans for his island, disturbing “Lolita” imagery, redacted foreign passports, and photos of high-profile figures. The Trump administration is also moving to dramatically ramp up denaturalization efforts, telling immigration officials to target up to 200 citizenship revocations per month next year — a massive escalation for a process that's historically rare. Trump's media company announced a surprise $6 billion merger with a nuclear fusion firm, briefly reviving its stock, while questions swirl around the recent killing of an MIT fusion scientist and the now-closed Brown University shooting case. In other news, Trump unveiled a very familiar-sounding “Patriot Games” and backed renaming the Kennedy Center after himself, RFK Jr. cut funding for major pediatric health programs while pushing new restrictions on gender-affirming care for minors, the government admitted liability in the deadly January DC plane crash, and The New Yorker launched a fully digitized 100-year archive — finally ending on a high note. Resources/Articles mentioned in this episode: The New Republic: Mike Johnson Sends Entire House Home Ahead of Epstein Files Deadline Axios: Latest Epstein photos include "Lolita" quotes written on a woman's body NYT: Trump Administration Aims to Strip More Foreign-Born Americans of Citizenship CNN: Trump's social media business is merging with a nuclear fusion company MIT: Nuno Loureiro, professor and director of MIT's Plasma Science and Fusion Center, dies at 47 WaPo: Kennedy Center board votes to rename to ‘Trump Kennedy Center' WaPo: American Academy of Pediatrics loses HHS funding after criticizing RFK Jr. NBC News: HHS moves to slash funding and access to care for transgender minors AP News: US government admits role in causing helicopter-plane collision that killed 67 in Washington New Yorker: The Entire New Yorker Archive Is Now Fully Digitized Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices
GBH's Adam Reilly and The Bay State Banner's Ron Mitchell join for Press Play media analysis. This week, they talk about media reaction to Trump's White House address, Brian McGrory returning to the Globe and a profile of the photographer who captured Trump staff for the Susie Wiles Vanity Fair profile. Boston Medical Center's Dr. Katherine Gergen Barnett on the CDC reversing its position on Hepatitis B vaccines for infants, cutting funding for the American Academy of Pediatrics, RFK Jr.'s move to ban gender affirming care for young people, and the so-called "Christmas Coronary effect." Atikin Rose is an up-and-coming R&B singer songwriter with a new EP due out next year. She joins for Live Music Friday alongside talent manager Rob Kelley-Morgan.Tony Williams and Peter Gwiazda celebrate 25 years of the Urban Nutcracker. Tony is the show's founder and creative visionary. Peter is a dancer with Les Ballets Trockadero de Monte Carlo.NBC10 Boston media maven Sue O'Connell talks Epstein files, Brian Walshe, and a NYTimes profile of the woman caught in that Coldplay kiss-cam last summer.
This week we go back in time 2 years to review a recent paper from 2023 about outcomes of cardiac transplantation in the adult congenital heart patient (ACHD). Little has been written on this topic until this very robust and large scale report. How do single ventricle ACHD patients fair at transplant and how do they compare to non-ACHD heart transplant recipients? Why might 1 and 3 year outcomes not be a 'fair' method of assessing outcomes in this very high risk patient group? How do HLHS patient outcomes compare with other single ventricles? Are there better ways to measure risk in this patient group and how might the data in this work inform risk stratification and management of failing Fontan patients in whom transplantation is being considered? These are amongst the questions posed this week to the week's expert, Dr Daphne Hsu who is Professor of Pediatrics at the Albert Einstein College of Medicine at The Children's Hospital at Montefiore.https://doi.org/10.1016/j.jacc.2023.06.037For those interested in learning more about Dr. Hsu, take a listen to episode #166 from June, 2021:https://www.spreaker.com/episode/pediheart-podcast-166-a-conversation-with-professor-daphne-hsu--45144274
In this December 19 episode of MAHA News, the hosts break down major health policy shifts shaping the MAHA movement. The discussion opens with President Trump's decision to reclassify marijuana from Schedule I to Schedule III, examining the medical, research, and financial implications for cannabis, CBD, and hemp industries. The show then turns to HHS actions targeting transgender surgeries for minors, including the removal of federal funding and scrutiny of organizations like the American Academy of Pediatrics. The conversation expands into Lyme disease, highlighting new federal acknowledgment of long-dismissed patient experiences and revelations surrounding its origins. The episode also covers food system reform, spotlighting local farm networks, raw milk resources, and corporate moves to remove harmful additives. The second half features an in-depth interview on red light therapy, exploring its science, applications, and potential benefits for inflammation, recovery, and chronic illness. The episode closes with reflections on health sovereignty, decentralization, and the broader cultural shift underway.
Disscuss experience of being a pediatric provider doing a podcast.
In this episode, I interview Dr. Shana Burstein, a second-year pediatric hematology-oncology fellow at Children's Healthcare of Atlanta. She received her MD from Albert Einstein College of Medicine in 2021, followed by a residency in Pediatrics at the Children's Hospital at Montefiore. Her current research interest is identifying novel genomic variants associated with pediatric cancer predisposition syndromes. During this conversation, Dr. Burstein shares the challenges and life lessons she learned along the way to becoming a physician. Further, she tells us about the incredible research she has performed from her work with calcium ion channels at Memorial Sloan Kettering Cancer Center to the computational biology work she is spearheading at Emory University. Lastly, we close the interview with Dr. Burstein sharing valuable advice for those aspiring to have a successful and healthy career in medicine.
Host: Jasmine T. Kency, M.D., Associate Professor of Internal Medicine and Pediatrics at the University of Mississippi Medical Center.Topic: Pneumonia, Fatigue, Anxiety/Depression, & Constipation. Email the show: remedy@mpbonline.org.If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.
The news to know for Thursday, December 18, 2025! What to know about President Trump's primetime address to the nation last night—how he rates his first year back in office, and why some say it was the wrong message. Also, why the U.S. is now suing the U.S. Virgin Islands, who is donating to the so-called Trump Accounts this time, and what a new version of history at the White House shows. Plus: what it could mean now that federal funding has been cut to the American Academy of Pediatrics, why the Academy Awards will look very different in a few years, and how music can be like food for your brain. Those stories and even more news to know in about 10 minutes! Join us every Mon-Fri for more daily news roundups! See sources: https://www.theNewsWorthy.com/shownotes Become an INSIDER to get AD-FREE episodes here: https://www.theNewsWorthy.com/insider Get The NewsWorthy MERCH here: https://thenewsworthy.dashery.com/ Sponsors: You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/NEWSWORTHY and using code NEWSWORTHY at checkout. Get 15% off OneSkin with the code NEWSWORTHY at https://www.oneskin.co/NEWSWORTHY #oneskinpod To advertise on our podcast, please reach out to ad-sales@libsyn.com
Howie Kurtz on President Trump's address to the nation, House Republicans offering an alternative to Obamacare, and Secretary RFK Jr. terminating grants to the American Academy of Pediatrics over federal vaccine policy disagreements. Follow Howie on Twitter: @HowardKurtz For more #MediaBuzz click here Learn more about your ad choices. Visit podcastchoices.com/adchoices
Websites talked about:The AAP Parenting WebsiteChildren's Hospital of PhiladelphiaEmail the show at kids@mpbonline.orgHost: Dr. Morgan McLeod, Asst. Professor of Pediatrics and Internal Medicine at the University of Mississippi Medical Center.If you enjoyed listening to this podcast, please consider contributing to MPB: https://donate.mpbfoundation.org/mspb/podcast Hosted on Acast. See acast.com/privacy for more information.
Anne Zink is a lecturer and senior fellow at the Yale School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A.B. Zink, N.C. McCann, and R.P. Walensky. From Crisis to Action — Policy Pathways to Reverse the Rise in Congenital Syphilis. N Engl J Med 2025;393:2388-2391.
Pediatrician Dr. Jill Schaffeld consults Dr. Scott Pentiuk and Dr. Alex Nasr from the Division of Gastroenterology, Hepatology, and Nutrition on ingested foreign bodies. Episode recorded on July 31, 2025. Resources discussed in this episode: Ingested Foreign Bodies - Community Practice Support Tool Financial Disclosure: The following relevant financial relationships have been disclosed: None All relevant financial relationships listed have been mitigated. Remaining persons in control of content have no relevant financial relationships. To Claim Credit: Click "Launch Activity." Click "Launch Website" to access and listen to the podcast. After listening to the entire podcast, click "Post Test" and complete. Accreditation In support of improving patient care, Cincinnati Children's Hospital Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Specific accreditation information will be provided for each activity. Physician: Cincinnati Children's designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing: This activity is approved for a maximum 0.50 continuing nursing education (CNE) contact hours. ABP MOCpt2: Completion of this CME activity, which includes learner assessment and feedback, enables the learner to earn up to 0.50 points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. Cincinnati Children's submits MOC/CC credit for board diplomates. Credits AMA PRA Category 1 Credits™ (0.50 hours), ABP MOC Part 2 (0.50 hours), CME - Non-Physician (Attendance) (0.50 hours), Nursing CE (0.50 hours)
https://funmedinstitute.com
Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability. Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeGod loves marriage, and abhors divorce. Oprah WinfreyEpisode Links:Relationship coach blames Oprah for pushing family estrangement 'for decades'; Expert says Winfrey helped normalize 'cutoff culture' as study shows a third of Americans are estranged from familyBREAKING: High Court Judge blocks Enoch Burke's family from courtroom.BREAKING: Florida AG sues WPATH, American Academy of Pediatrics, and The Endocrine Society for m*tilating kids in the name of “gender affirming care.”We wrote the HHS review on treatment for minors with gender dysphoria. We hope our critics actually read our report; Some may be skeptical of our findings, but we believe that our work speaks for itselfWhen we critique Trump, we often hear, “But where were your critiques of Biden?” Here's the difference: the Biden administration didn't use Jesus, the Bible, or Christian language to justify its policies. MAGA does, and large parts of the evangelical church cheer it on. Any administration that uses Christianity to defend something blatantly unchristian will get a Holy Post call-out. If you think it's a sin to have an abortion, then don't have an abortion." The Rev. Dr. Sarah Halverson-Cano of IUCC get teary-eyed at the thought that her daughter and granddaughter WON'T have access to abortion and "reproductive justice."
In Episode 3 of our hemolytic disease of the fetus and newborn (HDFN) series, host Paul Wirkus, MD, FAAP and guest Tim Bahr, MD, FAAP focus on clinical management and emerging consensus around care. Our discussion reviews key elements of the recently published consensus paper, including proposed guidelines for evaluation, monitoring, and treatment across the perinatal and neonatal periods. They address management of hyperbilirubinemia and anemia, escalation of care when disease severity increases, and the critical role of early recognition.We also explore high-risk presentations, including hydrops fetalis, and discuss delivery room considerations and coordination with Neonatal Resuscitation Program (NRP) protocols. Emphasis is placed on interdisciplinary collaboration between obstetrics, neonatology, hematology, and pediatrics to ensure timely intervention and continuity of care for affected infants.Have a question? Email questions@vcurb.com. They will be answered next week.For more information about available credit, visit vCurb.com.ACCME Accreditation StatementThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Colorado Medical Society through the joint providership of Kansas Chapter, American Academy of Pediatrics and Utah Chapter, AAP. Kansas Chapter, American Academy of Pediatrics is accredited by the Colorado Medical Society to provide continuing medical education for physicians. AMA Credit Designation StatementKansas Chapter, American Academy of Pediatrics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Osteomyelitis in children is common enough to miss and serious enough to matter. In this episode of PEM Currents, we review a practical, evidence-based approach to pediatric acute hematogenous osteomyelitis, focusing on diagnostic strategy, imaging decisions including FAST MRI, and modern antibiotic management. Topics include age-based microbiology, empiric and pathogen-directed antibiotic selection with dosing, criteria for early transition to oral therapy, and indications for orthopedic and infectious diseases consultation. Special considerations such as MRSA, Kingella kingae, daycare clustering, and shortened treatment durations are discussed with an emphasis on safe, high-value care. Learning Objectives After listening to this episode, learners will be able to: Identify the key clinical, laboratory, and imaging findings that support the diagnosis of acute hematogenous osteomyelitis in children, including indications for FAST MRI and contrast-enhanced MRI. Select and dose appropriate empiric and pathogen-directed antibiotic regimens for pediatric osteomyelitis based on patient age, illness severity, and local MRSA prevalence, and determine when early transition to oral therapy is appropriate. Determine when consultation with orthopedics and infectious diseases is indicated, and recognize clinical features that warrant prolonged therapy or more conservative management. References Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc. 2021;10(8):801-844. doi:10.1093/jpids/piab027 Woods CR, Bradley JS, Chatterjee A, et al. Clinical practice guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2023 guideline on diagnosis and management of acute bacterial arthritis in pediatrics. J Pediatric Infect Dis Soc. 2024;13(1):1-59. doi:10.1093/jpids/piad089 Stephan AM, Platt S, Levine DA, et al. A novel risk score to guide the evaluation of acute hematogenous osteomyelitis in children. Pediatrics. 2024;153(1):e2023063153. doi:10.1542/peds.2023-063153 Alhinai Z, Elahi M, Park S, et al. Prediction of adverse outcomes in pediatric acute hematogenous osteomyelitis. Clin Infect Dis. 2020;71(9):e454-e464. doi:10.1093/cid/ciaa211 Burns JD, Upasani VV, Bastrom TP, et al. Age and C-reactive protein associated with improved tissue pathogen identification in children with blood culture-negative osteomyelitis: results from the CORTICES multicenter database. J Pediatr Orthop. 2023;43(8):e603-e607. doi:10.1097/BPO.0000000000002448 Peltola H, Pääkkönen M. Acute osteomyelitis in children. N Engl J Med. 2014;370(4):352-360. doi:10.1056/NEJMra1213956 Transcript This transcript was provided via use of the Descript AI application Welcome to PEM Currents, the Pediatric Emergency Medicine Podcast. As always, I'm your host, Brad Sobolewski, and today we're covering osteomyelitis in children. We're going to talk about diagnosis and imaging, and then spend most of our time where practice variation still exists: antibiotic selection, dosing, duration, and the evidence supporting early transition to oral therapy. We'll also talk about when to involve orthopedics, infectious diseases, and whether daycare outbreaks of osteomyelitis are actually a thing. So what do I mean by pediatric osteomyelitis? In children, osteomyelitis is most commonly acute hematogenous osteomyelitis. That means bacteria seed the bone via the bloodstream. The metaphysis of long bones is particularly vulnerable due to vascular anatomy that favors bacterial deposition. Age matters. In neonates, transphyseal vessels allow infection to cross into joints, increasing the risk of concomitant septic arthritis. In older children, those vessels involute, and infection tends to remain metaphyseal and confined to bone rather than spreading into the joint. For children three months of age and older, empiric therapy must primarily cover Staphylococcus aureus, which remains the dominant pathogen. Other common organisms include group A streptococcus and Streptococcus pneumoniae. In children six to 36 months of age, especially those in daycare, Kingella kingae is an important and often underrecognized pathogen. Kingella infections are typically milder, may present with lower inflammatory markers, and frequently yield negative routine cultures. Kingella is usually susceptible to beta-lactams like cefazolin, but is consistently resistant to vancomycin and often resistant to clindamycin and antistaphylococcal penicillins. This has direct implications for empiric antibiotic selection. Common clinical features of osteomyelitis include fever, localized bone pain, refusal to bear weight, and pain with movement of an adjacent joint. Fever may be absent early, particularly with less virulent organisms like Kingella. A normal white blood cell count does not exclude osteomyelitis. Only about one-third of children present with leukocytosis. CRP and ESR are generally more useful, particularly CRP for monitoring response to therapy. No single CRP cutoff reliably diagnoses or excludes osteomyelitis in children. While CRP is elevated in most cases of acute hematogenous osteomyelitis, the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America note that high-quality data defining diagnostic thresholds are limited. A CRP above 20 milligrams per liter is commonly used to support clinical suspicion, with pooled sensitivity estimates around 80 to 85 percent, but no definitive value mandates the diagnosis. Lower values do not exclude disease, particularly in young children, as CRP is normal in up to 40 percent of Kingella kingae infections. CRP values tend to be higher in Staphylococcus aureus infections, especially MRSA, and higher levels are associated with complications such as abscess, bacteremia, and thrombosis, though specific cutoffs are not absolute. In summary, CRP is most useful for monitoring treatment response. It typically peaks two to four days after therapy initiation and declines rapidly with effective treatment, with a 50 percent reduction within four days seen in the majority of uncomplicated cases. Blood cultures should be obtained in all children with suspected osteomyelitis, ideally before starting antibiotics when feasible. In children, blood cultures alone can sometimes identify the pathogen. Plain radiographs are still recommended early, not because they're sensitive for acute osteomyelitis, but because they help exclude fracture, malignancy, or foreign body and establish a baseline. MRI with and without contrast is the preferred advanced imaging modality. MRI confirms the diagnosis, defines the extent of disease, and identifies complications such as subperiosteal abscess, physeal involvement, and concomitant septic arthritis. MRI findings can also guide the need for surgical consultation. Many pediatric centers now use FAST MRI protocols for suspected osteomyelitis, particularly from the emergency department. FAST MRI uses a limited sequence set, typically fluid-sensitive sequences like STIR or T2 with fat suppression, without contrast. These studies significantly reduce scan time, often avoid the need for sedation, and retain high sensitivity for bone marrow edema and soft tissue inflammation. FAST MRI is particularly useful when the clinical question is binary: is there osteomyelitis or not? It's most appropriate in stable children without high concern for abscess, multifocal disease, or surgical complications. If FAST MRI is positive, a full contrast-enhanced MRI may still be needed to delineate abscesses, growth plate involvement, or adjacent septic arthritis. If FAST MRI is negative but clinical suspicion remains high, further imaging may still be necessary. The Pediatric Infectious Diseases Society and the Infectious Diseases Society of America recommend empiric antibiotic selection based on regional MRSA prevalence, patient age, and illness severity, with definitive therapy guided by culture results and susceptibilities. Empiric therapy should never be delayed in an ill-appearing or septic child. In well-appearing, stable children, antibiotics may be briefly delayed to obtain imaging or tissue sampling, but this requires close inpatient observation. For children three months and older with non–life-threatening disease, empiric therapy hinges on local MRSA rates. In regions with low community-acquired MRSA prevalence, generally under 10 percent, reasonable empiric options include cefazolin, oxacillin, or nafcillin. When MRSA prevalence exceeds 10 to 20 percent, empiric therapy should include an MRSA-active agent. Clindamycin is appropriate when local resistance rates are low, while vancomycin is preferred when clindamycin resistance is common or the child has had significant healthcare exposure. For children with severe disease or sepsis, vancomycin is generally preferred regardless of local MRSA prevalence. Some experts recommend combining vancomycin with oxacillin or nafcillin to ensure optimal coverage for MSSA, group A streptococcus, and MRSA. In toxin-mediated or high-inoculum infections, the addition of clindamycin may be beneficial due to protein synthesis inhibition. Typical IV dosing includes cefazolin 100 to 150 milligrams per kilogram per day divided every eight hours; oxacillin or nafcillin 150 to 200 milligrams per kilogram per day divided every six hours; clindamycin 30 to 40 milligrams per kilogram per day divided every six to eight hours; and vancomycin 15 milligrams per kilogram every six hours for serious infections, with appropriate monitoring. Ceftaroline or daptomycin may be considered in select MRSA cases when first-line agents are unsuitable. For methicillin-susceptible Staphylococcus aureus, first-generation cephalosporins or antistaphylococcal penicillins remain the preferred parenteral agents. For oral therapy, high-dose cephalexin, 75 to 100 milligrams per kilogram per day divided every six hours, is preferred. Clindamycin is an alternative when beta-lactams cannot be used. For clindamycin-susceptible MRSA, clindamycin is the preferred IV and oral agent due to excellent bioavailability and bone penetration, and it avoids the renal toxicity associated with vancomycin. For clindamycin-resistant MRSA, vancomycin or ceftaroline are preferred IV agents. Oral options are limited, and linezolid is generally the preferred oral agent when transition is possible. Daptomycin may be used parenterally in children older than one year without pulmonary involvement, typically with infectious diseases and pharmacy input. Beta-lactams remain the drugs of choice for Kingella kingae, Streptococcus pyogenes, and Streptococcus pneumoniae. Vancomycin has no activity against Kingella, and clindamycin is often ineffective. For Salmonella osteomyelitis, typically seen in children with sickle cell disease, third-generation cephalosporins or fluoroquinolones are used. In underimmunized children under four years, consider Haemophilus influenzae type b, with therapy guided by beta-lactamase production. Doxycycline has not been prospectively studied in pediatric acute hematogenous osteomyelitis. There are theoretical concerns about reduced activity in infected bone and risks related to prolonged therapy. While short courses are safe for certain infections, the longer durations required for osteomyelitis increase the risk of adverse effects. Doxycycline should be considered only when no other active oral option is available, typically in older children, and with infectious diseases consultation. It is not appropriate for routine treatment. Many hospitals automatically consult orthopedics when children are admitted with osteomyelitis, and this is appropriate. Early orthopedic consultation should be viewed as team-based care, not failure of medical management. Consult orthopedics when MRI shows abscess or extensive disease, there is concern for septic arthritis, the child fails to improve within 48 to 72 hours, imaging suggests devitalized bone or growth plate involvement, there is a pathologic fracture, the patient is a neonate, or diagnostic bone sampling or operative drainage is being considered. Routine surgical debridement is not required for uncomplicated cases. Infectious diseases consultation is also often automatic and supported by guidelines. ID is particularly valuable for antibiotic selection, dosing, IV-to-oral transition, duration decisions, bacteremia management, adverse reactions, and salvage regimens. Even in straightforward cases, ID involvement often facilitates shorter IV courses and earlier oral transition. Osteomyelitis is generally not contagious, and clustering is uncommon for Staphylococcus aureus. Kingella kingae is the key exception. It colonizes the oropharynx of young children and spreads via close contact. Clusters of invasive Kingelladisease have been documented in daycare settings. Suspicion should be higher in children six to 36 months from the same daycare, with recent viral illness, mild systemic symptoms, refusal to bear weight, modest CRP elevation, and negative routine cultures unless PCR testing is used. Public health intervention is not typically required, but awareness is critical. There is no minimum required duration of IV therapy for uncomplicated acute hematogenous osteomyelitis. Transition to oral therapy should be based on clinical improvement plus CRP decline. Many children meet criteria within two to six days. Oral antibiotics must be dosed higher than standard outpatient regimens to ensure adequate bone penetration. Common regimens include high-dose cephalexin, clindamycin, or linezolid in select cases. The oral agent should mirror the IV agent that produced clinical improvement. Total duration is typically three to four weeks, and in many cases 15 to 20 days is sufficient. MRSA infections or complicated cases usually require four to six weeks. Early oral transition yields outcomes comparable to prolonged IV therapy with fewer complications. Most treatment-related complications occur during parenteral therapy, largely due to catheter-related issues. Take-home points: osteomyelitis in children is a clinical diagnosis supported by labs and MRI. Empiric antibiotics should be guided by age, illness severity, and local MRSA prevalence. Early transition to high-dose oral therapy is safe and effective when clinical response and CRP support it. Orthopedics and infectious diseases consultation improve care and reduce variation. FAST MRI is changing how we diagnose osteomyelitis. Daycare clustering is uncommon except with Kingella kingae. That's all for this episode. If there are other topics you'd like us to cover, let me know. If you have the time, leave a review on your favorite podcast platform. It helps more people find the show and learn from it. For PEM Currents, this has been Brad Sobolewski. See you next time.
In this episode, we speak with Dr. Stan Sonu, Associate Professor of Internal Medicine and Pediatrics at Emory University School of Medicine and Medical Director for Child Advocacy at Children's Healthcare of Atlanta. Dr. Sonu shares his insights on adverse childhood experiences (ACEs), relational health, and trauma-informed care, focusing on how clinicians and schools can support resilience and wellbeing in children and families.We dive into Dr. Sonu's paradigm of “what's strong with you” instead of “what's wrong with you?”, and explore the fascinating concept of systemic empathy—how organizations and systems can create environments that nurture and protect children's relational health.Dr. Sonu also highlights innovative programs like Strong 4 Life at Children's Healthcare of Atlanta and the Health-Law Partnership (HeLP), a collaborative addressing health-harming legal issues for low-income families.He references valuable resources for clinicians, educators, and families, including the work of Dan Siegel, Interpersonal Neurobiology, and community support services at Grady Memorial Hospital.Listeners will gain actionable ideas for integrating trauma-informed principles into their own practice, classrooms, or organizations, and be inspired to shift from focusing on deficits to recognizing and building on strengths in children and families.Resources Mentioned in This Episode:https://www.strong4life.com/en/our-experts/stan-sonuGrady Memorial HospitalDan Siegel Books & ResourcesInterpersonal Neurobiology ResourcesHealth-Law Partnership (HeLP)
In this episode of Bowel Sounds, hosts Dr. Amber Hildreth and Dr. Peter Lu talk to Dr. Tom Wallach, Assistant Professor of Pediatrics at SUNY Downstate, Chief of Pediatric Gastroenterology, Pediatric GI Fellowship director, and Research Director of Pediatrics. We talk about experience based research and how to implement these tools into medical education.Learning objectivesDefine experience based researchUnderstand how to incorporate experience based research into medical educationExplore the variety of tools available to scientists at all levels of training to conduct researchSupport the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.
This week we speak with noted congenital cardiologist Professor Krishna Kumar of the Amrita Institute in Cochin, India and discuss his recent work on inequities in congenital heart care in the world. Over 90% of patients with CHD do not have access to care in the globe today. What is the path forward to improve this sobering statistic? How can a World Health Assembly resolution practically help improve care in LMIC countries worldwide? Dr. Kumar shares his deep insights.This week we also briefly note the passing of the wonderful and caring pediatric cardiologist Dr. Sangeetha Viswanathan of Chennai, India who tragically died suddenly this week while attending the World Congress events in Hong Kong. Dr. Kumar's words regarding his friend, former fellow and colleague are read in remembrance of this wonderful and giving cardiologist whose loss will be deeply felt by her patients, family and friends. DOI: 10.1016/j.jacc.2025.07.070
In this episode, Jess and special guest co-host Dr. Elana Pearl Ben-Joseph welcome Dr. Susan Kressly, President of the American Academy of Pediatrics, for an in-depth discussion about the future of pediatric healthcare. The scientists explore the urgent need to redesign healthcare systems to prioritize prevention and wellness rather than reactive treatment. Dr. Kressly shares valuable insights on building trust between pediatricians and parents, addressing the critical challenges facing healthcare delivery today. The conversation examines vaccine confidence issues while emphasizing the importance of human-centered approaches to medical care. Throughout the episode, the experts highlight both the obstacles and opportunities in pediatric healthcare, offering a hopeful vision for creating better health outcomes for children and supporting families more effectively in navigating the complex healthcare landscape. Watch the conversation on YouTube: https://youtu.be/X8Bil_aW2UA (00:00) Intro (02:15) What Is A News Item That Caught Your Attention And Why? (06:54) Supporting Pediatricians In A Challenging Environment (09:14) How Can Parents Navigate Today's Healthcare System? (13:56) Vaccine Hesitancy Report Findings (16:05) Building Trust In Vaccination And Healthcare (26:22) Hope That Healthcare Is Improving? (29:59) What Is Giving Hope In Public Health? https://aap.org https://healthychildren.org https://www.pewresearch.org/science/2024/11/14/public-trust-in-scientists-and-views-on-their-role-in-policymaking/ https://www.pewresearch.org/science/2025/11/18/how-do-americans-view-childhood-vaccines-vaccine-research-and-policy/ https://www.instagram.com/p/DRNCjgwko6u/ ----------------------------------------------------------------------------------------------------------------------- Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Learn more about your ad choices. Visit megaphone.fm/adchoices
Dr. Sue Kressly, president of the American Academy of Pediatrics, joins Dr. Vin Gupta of Meidas Health for an emergency episode to discuss the recommended changes to the Hepatitis B vaccine schedule for babies. She clearly explains why the proposed test-and-immunize strategy would take us back decades to a time when tens of thousands of children were needlessly infected with a serious virus. Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2026 Ivy Podcast Discovery LLC
